The estimated Net Worth of Jeffrey M Jonas is at least $60.3 Million dollars as of 1 September 2023. Jeffrey Jonas owns over 13,809 units of Sage Therapeutics Inc stock worth over $110,845 and over the last 10 years he sold SAGE stock worth over $50,295,438. In addition, he makes $9,902,080 as President und Chief Executive Officer and Director at Sage Therapeutics Inc.
Sign up
Jeffrey Jonas SAGE stock SEC Form 4 insiders trading
Jeffrey has made over 22 trades of the Sage Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 13,809 units of SAGE stock worth $100,391 on 1 September 2023.
The largest trade he's ever made was exercising 276,600 units of Sage Therapeutics Inc stock on 15 June 2015 worth over $124,470. On average, Jeffrey trades about 17,923 units every 64 days since 2014. As of 1 September 2023 he still owns at least 14,799 units of Sage Therapeutics Inc stock.
You can see the complete history of Jeffrey Jonas stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jeffrey Jonas biography
Dr. Jeffrey M. Jonas M.D. serves as President, Chief Executive Officer and Director of the Company. Dr. Jonas served as the President of the Regenerative Medicine Division of Shire plc, or Shire, a global specialty pharmaceutical company, and from 2008 to 2012 as Senior Vice President of Research and Development, Pharmaceuticals at Shire. From 2007 to 2008, Dr. Jonas served as the Executive Vice President of Ionis Pharmaceuticals, Inc., formerly known as ISIS Pharmaceuticals, Inc. and from 2006 to 2007 as Chief Medical Officer and Executive Vice President of Forest Laboratories, Inc. and from 1991 to 1996 in senior-level positions at Upjohn Laboratories. Dr. Jonas also founded AVAX Technologies, Inc. and SCEPTOR Industries, Inc., where he served as the Chief Executive Officer, President and a Director. Dr. Jonas currently serves on the board of directors for Generation Bio Co. and Karuna Pharmaceuticals, Inc., or Karuna. Dr. Jonas has published more than 70 scientific papers and chapters, authored more than 100 books, scientific articles and abstracts, and has received numerous awards. Dr. Jonas received his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard Medical School, and he served as Chief Resident in psychopharmacology at McLean Hospital, Harvard Medical School. Dr. Jonas’ qualifications to sit on our Board of Directors include more than 20 years of experience on both the scientific and business sides of the pharmaceutical and healthcare industries, particularly in the central nervous system field.
What is the salary of Jeffrey Jonas?
As the President und Chief Executive Officer and Director of Sage Therapeutics Inc, the total compensation of Jeffrey Jonas at Sage Therapeutics Inc is $9,902,080. There are no executives at Sage Therapeutics Inc getting paid more.
How old is Jeffrey Jonas?
Jeffrey Jonas is 67, he's been the President und Chief Executive Officer and Director of Sage Therapeutics Inc since 2013. There are 1 older and 16 younger executives at Sage Therapeutics Inc. The oldest executive at Sage Therapeutics Inc is Dr. Jeffrey M. Jonas, 68, who is the Chief Innovation Officer, Chair of the Science & Technology Forum and Director.
What's Jeffrey Jonas's mailing address?
Jeffrey's mailing address filed with the SEC is C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE, MA, 02142.
Insiders trading at Sage Therapeutics Inc
Over the last 10 years, insiders at Sage Therapeutics Inc have traded over $190,046,458 worth of Sage Therapeutics Inc stock and bought 150,092 units worth $6,260,297 . The most active insiders traders include Kevin P Starr, Robert Nelsen und Michael F Cola. On average, Sage Therapeutics Inc executives and independent directors trade stock every 32 days with the average trade being worth of $256,667. The most recent stock trade was executed by Kimi Iguchi on 2 January 2024, trading 1,642 units of SAGE stock currently worth $2,233.
What does Sage Therapeutics Inc do?
sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.
What does Sage Therapeutics Inc's logo look like?
Complete history of Jeffrey Jonas stock trades at Sage Therapeutics Inc, Karuna Therapeutics Inc und Generation Bio Co
Sage Therapeutics Inc executives and stock owners
Sage Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Jeffrey Jonas,
President, Chief Executive Officer and Director -
Michael Cloonan,
Chief Operating Officer -
Stephen Kanes,
Chief Medical Officer -
Anne Cook,
Senior Vice President, General Counsel, Secretary -
Kimi Iguchi,
Chief Financial Officer, Treasurer -
Albert Robichaud,
Chief Scientific Officer -
Elizabeth Barrett,
Independent Director -
George Golumbeski,
Independent Director -
Dr. Jeffrey M. Jonas,
Chief Innovation Officer, Chair of the Science & Technology Forum and Director -
Kevin Starr,
Independent Chairman of the Board -
Michael Cola,
Independent Director -
James Frates,
Independent Director -
Steven Paul,
Independent Director -
Geno Germano,
Independent Director -
Asha Nayak,
Independent Director -
Anne Marie Cook,
Sr. VP, Gen. Counsel & Sec. -
Dr. Albert J. Robichaud Ph.D.,
Chief Scientific Officer -
Kimi E. Iguchi,
CFO & Treasurer -
Barry E. Greene,
Pres, CEO & Director -
Barry Greene,
Director -
Dr. Jim Doherty Ph.D.,
Chief Devel. Officer -
Dr. Amy Schacterle Ph.D.,
Sr. VP of R&D Strategy and Bus. Management -
Erin E. Lanciani,
Chief People & Experience Officer -
Helen Rubinstein,
Investor Relations Officer -
Matt Lasmanis,
Chief Technology & Innovation Officer -
Rock Ventures Ii, L.P.Third...,
-
Howard H Pien,
-
Thomas Anderson,
See Remarks -
Robert Nelsen,
Director -
Venture Fund Vii Lparch Ven...,
-
Rock Ventures Ii, L.P.Third...,
-
Laura Gault,
Chief Medical Officer -
Jessica Federer,
-
Christopher Benecchi,
Chief Business Officer